The short answer
Coverage reported that Eli Lilly halted a bimagrumab and tirzepatide trial. The registry shows NCT06901349 as withdrawn with enrolment of zero, while three other bimagrumab trials are completed or recruiting. That is a different picture from a programme being stopped.
Key facts
- NCT06901349
- Phase 2, WITHDRAWN, n=0
- NCT06643728
- Phase 2, completed, n=252
- NCT06890611
- Phase 1, completed, n=125
- NCT05933499
- Phase 2, recruiting, n=63
- Bimagrumab code
- LY3985863
- Withdrawn means
- Never enrolled anyone
- Registry checked
- ClinicalTrials.gov, 21 November 2026
The distinction that changes the meaning
Registries use withdrawn and terminated for different situations. Terminated means a study started, enrolled participants and then stopped. Withdrawn means it never enrolled anyone: the record exists because the study was registered, and it closed before beginning. NCT06901349 is withdrawn with enrolment recorded as zero.
Why that matters for interpretation
A terminated trial can indicate a safety finding or a futility analysis, where something was learned from participants and acted on. A withdrawn trial with no enrolment cannot have produced any finding at all, because nobody was ever in it. Whatever the reason, it was not evidence from that study.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the rest of the programme looks like
NCT06643728 is a Phase 2 investigating weight management with bimagrumab and tirzepatide. It completed on 27 October 2026 with 252 participants (primary completion 16 January 2026). NCT06890611 is a completed Phase 1 with 125. NCT05933499 is recruiting with 63, examining body composition, insulin sensitivity and bone. Three studies at various stages alongside one that never started.
Why the bone endpoint is worth noticing
NCT05933499's registered title includes bone alongside body composition and insulin sensitivity. That reflects the point the fat-free mass literature keeps making: the compartment is not only muscle, and a trial measuring bone separately is treating it as its own question rather than folding it into a lean mass figure.
How to read a programme rather than a headline
Search the compound rather than the news. A registry search returns every registered study with its status, phase and enrolment, which describes what is actually happening more reliably than any single report about one trial. This site has already found a compound whose most-cited trial identifier pointed at an entirely different drug.
Regulatory position
Bimagrumab holds no marketing authorisation for obesity anywhere and is investigational. All the trials described are conducted under clinical supervision with ethics approval. Nothing supplied here is related to bimagrumab or to tirzepatide.
Quick reference
| Registration | Phase | Status | Enrolment |
|---|---|---|---|
| NCT06901349 | 2 | Withdrawn | 0 |
| NCT06643728 | 2 | Completed | 252 |
| NCT06890611 | 1 | Completed | 125 |
| NCT05933499 | 2 | Recruiting | 63 |
Frequently asked questions
What is the difference between withdrawn and terminated?
Terminated means a study enrolled participants and then stopped. Withdrawn means it never enrolled anyone at all.
Was the bimagrumab programme stopped?
The registry shows one withdrawn study with zero enrolment alongside three others, two completed and one recruiting (ClinicalTrials.gov, 21 November 2026).
How should I check a programme's status?
Search the compound on ClinicalTrials.gov rather than relying on a report about one trial. Every registered study returns with its status, phase and enrolment.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov · Bimagrumab and tirzepatide, weight management (NCT06643728)clinicaltrials.gov
- TrialClinicalTrials.gov · Bimagrumab and tirzepatide (NCT06901349)clinicaltrials.gov
- TrialClinicalTrials.gov · Tirzepatide and bimagrumab, body composition, insulin sensitivity and bone (NCT05933499)clinicaltrials.gov
- PubMedHeymsfield SB et al., Bimagrumab vs placebo on body fat mass. JAMA Netw Open 2021 (PMID 33439265)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- What the Systematic Reviews Say About Children and AdolescentsTwo 2025 systematic reviews assessed GLP-1 agonists in children and adolescents. What review-level evidence establishes, and what is still missing.
- What the Human Studies Have FoundA BMJ Scandinavian cohort, a JAMA Network Open analysis of 13 cancers, and a 2025 meta-analysis of randomised trials. What each design can support.
- Semaglutide in Obesity-Related Heart FailureKosiborod 2023 in NEJM and a pooled Lancet analysis in 2024. Randomised evidence in HFpEF, which is a stronger design than the observational work.
- STRIDE and the Qualifier That Keeps Getting DroppedA phase 3b randomised trial of semaglutide in symptomatic PAD - and type 2 diabetes. The diabetes criterion is in the title and rarely survives summary.
- A Trial That Had to Move Two Things at Once407 participants, Phase 3, with co-primary endpoints of body weight and WOMAC pain score. Published in NEJM in October 2024.